Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company focused on discovering and developing innovative medicines in areas of high unmet medical need. The company's research and development portfolio is primarily concentrated on oncology, pain management, and autoimmune diseases. By leveraging its proprietary technology platforms, Nektar aims to create therapies that improve patient outcomes and quality of life. Their projects range from preclinical research to late-stage clinical trials, with the objective to bring new, effective treatments to market. Through strategic collaborations and partnerships, Nektar Therapeutics seeks to expand its pipeline and accelerate the development of novel therapeutics.